What is Roche Personalised Healthcare all about?

It is more important to know what sort of person has a disease than what sort of disease a person has.

Personalised Healthcare (PHC) is about providing the right treatment for the right group of patients. Roche’s strengths in pharmaceuticals and diagnostics along with advances in science and technology have made fitting treatments to patients possible. Did you know that previously, only five out of ten patients, on average, actually benefited from their treatment? Today, up to 80% of patients respond to their targeted therapies.

From better disease understanding to supporting regulatory approvals

What has changed?

  • From primarily looking at the disease location in the body ... to identifying the root cause of a disease
  • From trial and error ... to putting the uniqueness of patients first
  • From one-size-fits all medicines ... to targeted therapy


... all patients diagnosed with a disease received the same medicine. Although, one-size-fits-all therapies do work for some patients, they can be ineffective and/or even cause side effects for others.


... doctors can identify the root causes of disease and therefore better predict how well a patient is going to respond to the treatment. Roche Personalised Healthcare puts the uniqueness of patients first. With the help of sophisticated diagnostic tests and tools, specific genetic defects or other malfunctions can be detected and treated.

In oncology, where PHC has advanced fastest we are now aware that there are 250 to 300 types and subtypes of cancer.


Do you remember your last visit to the physician? Presumably, the notes were taken down in your physical file and will later on be stored in an archive. This might fundamentally change in the following years, as the digital revolution is at the onset of transforming the healthcare industry. Both research and medical practice are expected to produce*, integrate and use increasingly large data sets on patients, diseases and treatments. By mining this data, researchers and physicians will be able to gain new insights with regard to correlations of patient sub-populations. Hence they will be able better develop, match and continuously optimise treatment for patients.

*E.g. clinical trial data

Who benefits?



  • Improved quality of life and lifetime gained
  • Fewer unnecessary treatments, side effects and associated costs
  • Better and more predictable clinical outcomes
  • Increased confidence in treatment and better improvement of outcomes for patients
  • Patients see the benefit of their therapy more clearly, hence they better collaborate
  • Improved evidence simplifying decision-making
  • Optimised use of healthcare resources
  • Improved clinical outcomes

Which diseases can today be treated with Roche Personalised Healthcare?

Metastatic breast cancer

Metastatic breast cancer

15 – 20% of patients are HER2-positive

Non-small cell lung cancer

Non-small cell lung cancer

10 – 30% of patients are EGFR-positive and more than 8% are ALK-positive

Viral infections

Viral infections

Hepatitis B, Hepatitis C, HIV

Metastatic melanoma<

Metastatic melanoma

~ 50% of patients are BRAF-positive

Stomach cancer

Stomach cancer

16 – 22% of patients are HER2-positive

Targeted treatments are based on the molecular causes of disease. That means they operate based on the presence of biomarkers and through companion diagnostic tests indicating mutations or genetic expressions in the patients' tissue. For example, in the past non-small cell lung cancer (NSCLC) was just diagnosed as NSCLC. Today we know over a dozen gene mutations that can play a role in this type of cancer. Therefore, the detection of biomarkers via diagnostic tests allows for a more targeted treatment patients can benefit from.

Mutations potentially causing non-small cell lung cancer.

What do people say?